- Home
- RMCO vs CING Comparison
RMCO vs CING Comparison
Compare RMCO & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- CING
- Stock Information
- Founded
- RMCO 2021
- CING 2012
- Country
- RMCO United States
- CING United States
- Employees
- RMCO N/A
- CING N/A
- Industry
- RMCO Multi-Sector Companies
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- CING Health Care
- Exchange
- RMCO Nasdaq
- CING Nasdaq
- Market Cap
- RMCO 14.9M
- CING 13.1M
- IPO Year
- RMCO N/A
- CING 2021
- Fundamental
- Price
- RMCO $1.22
- CING $4.25
- Analyst Decision
- RMCO
- CING Strong Buy
- Analyst Count
- RMCO 0
- CING 4
- Target Price
- RMCO N/A
- CING $30.67
- AVG Volume (30 Days)
- RMCO 46.5K
- CING 97.0K
- Earning Date
- RMCO 05-23-2025
- CING 05-07-2025
- Dividend Yield
- RMCO N/A
- CING N/A
- EPS Growth
- RMCO N/A
- CING N/A
- EPS
- RMCO N/A
- CING N/A
- Revenue
- RMCO $807,089.00
- CING N/A
- Revenue This Year
- RMCO N/A
- CING N/A
- Revenue Next Year
- RMCO N/A
- CING N/A
- P/E Ratio
- RMCO N/A
- CING N/A
- Revenue Growth
- RMCO 65.21
- CING N/A
- 52 Week Low
- RMCO $0.70
- CING $1.80
- 52 Week High
- RMCO $1.59
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- RMCO 65.32
- CING 56.43
- Support Level
- RMCO $1.12
- CING $4.03
- Resistance Level
- RMCO $1.28
- CING $4.61
- Average True Range (ATR)
- RMCO 0.10
- CING 0.31
- MACD
- RMCO 0.02
- CING 0.04
- Stochastic Oscillator
- RMCO 83.56
- CING 70.25
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.